TKIs for Advanced HCC in the Second Line and Beyond

In this podcast episode, experts Josep M. Llovet, MD, PhD, and Univ. Prof. Markus Peck-Radosavljevic, MD, MBA, discuss the role of tyrosine kinase inhibitors in treating patients with advanced HCC in the second line and beyond.

Om Podcasten

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.